Lapatinib is a drug that is approved to treat patients with HER2 positive, metastatic, trastuzumab refractory breast cancer when used in combination with capecitabine as it has been shown to prolong median survival time [139]. This evidence concerns the gene ERBB2 and breast carcinoma.